All aboard! In RVV yesterday as well
Printable View
All aboard! In RVV yesterday as well
is there something i'm missing about RVV? what is all the hype about?
RVV will focus on Infectious Diseases, including COVID-19, and Rare Disorders:
1. Bucillamine Infectious Diseases (COVID-19) Filing IND IND for Phase 3 Market size =TBD
2. Psilocybin Undisclosed Pre-clinical Target FDA Orphan Status + $500M
3. Psilocybin Undisclosed Multiple Indications Pre-clinical Target FDA Orphan Status Market size =TBD
4. CBD Liver Diseases (Autoimmune Hepatitis) Filing IND Received FDA Orphan Status IND for Phase 2 Psilocybin Undisclosed Pre-clinical Target FDA Orphan Status + $500M Psilocybin Undisclosed Multiple Indications Pre-clinical Target FDA Orphan Status TBD + $100M 50k US Population
Infectious Disease Opportunity:
Focus on Bucillamine in the treatment of infectious diseases § Well-known safety profile and prescribed for arthritis in Japan and South Korea for over 30 years §
Revive’s clinical history with Bucillamine § Obtained 2 FDA INDs with Bucillamine and FDA orphan drug status § FDA Phase 2 clinical study for acute gout flares and cystinuria § Bucillamine (BUC) scientific rationale as an intervention for COVID-19 (see Appendix) § BUC is 16x more potent than particularly N-acetylcysteine (NAC); NAC has shown to prevent acute lung injury caused by influenza virus BUC shown superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection
BUC also shown to prevent oxidative and reperfusion injury in heart and liver tissues §
BUC proven safety and MOA similar to NAC, but with much higher potency §
Advancing towards FDA Phase 3 clinical study for COVID-19
Pschedelic Opportunity
§ Acquired Psilocin Pharma Corp. § Derrick Welch, Founder with 14 years of HC experience; 5 years in Cannabis § Worked with Xanthic Bio Pharma and Green Growth Brands
§ Developed water Soluble THC and CBD products (Beverages, effervescent tablets)
§ Novel Psilocybin formulations, extraction and purification methods
§ Suited for pharmaceutical development and recreational markets where legal
§ Patent pending Psilocybin formulations (natural synthetic derived)
§ Capsules, Sublingual Spray, Gel Cap, Effervescent Tablets, and Oral Strips
§ Targeting rare diseases, mental health and addiction
LIVER DISEASE OPPORTUNITY
§ Focus on Autoimmune Hepatitis (AIH) § AIH - rare disease (~ 76k patients in US) causing liver inflammation • Drawbacks of current therapies (steroids): Severe side effects in 13%, relapse after drug withdrawal in 50%-86%*
§ Obtained FDA orphan drug status for CBD in the treatment of AIH
§ Seeking to file FDA IND to conduct Phase 2 clinical study in patient affected by AIH § Big Pharma interest in liver diseases § Allergan acquisition of Tobira for $1.7 billion
§ Novartis license of Conatus drug for $650 million
§ Gilead acquisition of Nimbus for $1.2 billion
STRATEGIC PARTNERS:
A. Pharm Olam
B.Psilocin Corp (Aquired)
C.Wisconsin University
D.South Carolina University
E.WARF Wisconsin Alumni Research Foundation
F.Sanyal Biotechnology
Seems like a good crap shoot to me
Neon and lobe and the gainers for me this morning.
I know this is emerging market stuff, but does anyone have a DD formula for this? :angel:
Finally got a small position in RVV to join in on the ride.
For those on NEON, what's your price target?
Its all highly speculative. My DD is reading the investor presentations in detail and then deciding if it sounds less like bullshit then average. All investor presentations are at least 60% bullshit, but some have been 99% or higher. I don't buy those.
- - - Updated - - -
I would normally prefer some kind of cash flow, debt, earnings per share kind of thing. But, these are all zeros.
i sold my RVV today, you're better off going with MMED or CBDT
Neon turns me off so much.
In order of faith I would rank my psychedelic investments from NUMI —> MYCO —> CYBN —> HAVN —> ENBI —> RVV..
Sold FTRP a little while back.
My dd is firsthand experience and knowing the potential of the medicine in certain settings, checking the management team and the clinical trials they want to do and how they plan to earn revenue. This is entirely different than cannabis, but I will probably be a short term player once it lifts off.
I agree with NUMI being the best investment. Also a great one to trade with daily swings.
I enjoyed my swings on numi.
[QUOTE=BavarianBeast;4953687]Neon turns me off so much.
In order of faith I would rank my psychedelic investments from NUMI —> MYCO —> CYBN —> HAVN —> ENBI —> RVV..
/QUOTE]
Really? HAVN has been the dog in this portfolio for me.
Kinda figure it is too late to get on the MMED and NUMI train?
I added to Numi today. It's sale day (lets just hope there isn't any more sales after today)